Chick-fil-A has partnered with Faction, a California-based company that develops autonomous fleets. Photo courtesy of Faction

This article was written by CultureMap Columnist Ken Hoffman and originally appeared on CultureMap's Hoffman's Houston editorial series.

Next time you order “curbside delivery” from the Chick-fil-A on Kirby Drive and the Southwest Freeway, one of the top performing Chick-fil-A’s in the country, don’t be surprised if your Spicy Chicken Sandwich and waffle fries are delivered by a driverless three-wheeled electric vehicle that looks like a cross between a Big Wheels kiddie car and the Mars Rover.

It’s a first in Houston. Chick-fil-A has partnered with Faction, a California-based company that develops autonomous (driverless) fleets. Earlier this week I met with Ain McKendrick, the founder and CEO of Faction, who explained how Chick-fil-A’s futuristic curbside delivery system works.

The key word is curbside. Unlike popular food deliverers like DoorDash and UberEats, Faction’s robotic vehicles don’t involve a human driver who will bring the food to your door, with the expectation of receiving a tip.

When a Faction vehicle delivers your food, you will get a text that the vehicle has arrived, and you’ll walk to the curb and pick up your food from the car that’s parked in front of your house. Throw some clothes on, please. The neighbors may see you.

When you order from the Kirby/Southwest Chick-fil-A on the Chick-fil-A app, and click on delivery, you’ll be given a choice of how you want your food brought to your house. You can still request DoorDash or another service. If you choose “curbside delivery,” watch for a Faction vehicle pulling up in front of your house. You’ll pop open the storage door, open the separate boxes that keep your sandwiches and fries toasty and your soft drinks cold, and run back into your house to dig in.

Right now, the Kirby/Southwest Freeway Chick-fil-A is using two Faction vehicles to supplement the regular delivery cars during crush time. Faction promises (they couch the claim by saying “estimates”) you’ll get your food within 30 minutes. Currently human “supervisors” are doing ride-alongs while the vehicles are mapping out the restaurant’s four-mile delivery area. Faction follows its vehicles’ progress on a video board at home base making sure each delivery goes right.

The electric vehicles are licensed and insured and can do 75 miles-per-hour on highways. But because of Houston’s notorious traffic, Faction has programmed the vehicles to stay on surface streets and below the speed limit. That’s how I get around, too. I got tired of that inexplicable traffic jam on the Southwest Freeway when it bends toward downtown.

McKendrick said the driverless vehicles will have memorized Houston streets well enough by August to operate without human supervisors.

Will customers be OK with their Chick-fil-A food delivered by driverless vehicles? So far it’s not a problem. In fact, McKendrick said some customers wait outside with their phone cameras ready so they can share photos of the delivery. Sharing their waffle fries is a different story.

I’m a skeptic when it comes to electric and driverless vehicles. I asked McKendrick …

What happens if a dog runs in front of a Faction vehicle? He said it will automatically stop for the pooch.

What if there’s a children’s birthday party on my block and there’s no parking space in front of my house? He said the vehicle will pull to the side and flash warning lights until the customer picks up their food.

So what’s in it for Chick-fil-A to partner with Faction? Kirby/Southwest Freeway Chick-fil-A owner Jesse Chaluh said it’s a more efficient way of offering delivery service to his customers. He thinks that his restaurant eventually will require five or more Faction vehicles to handle the demand.

While each vehicle currently delivers one order to one customer per run, eventually the technology will improve where each vehicle will be able to make several deliveries with each foray onto the streets of Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”